Bachleda Mark 4

What Happened

• Mark Bachleda, a director of Lyell Immunopharma (LYEL), received a grant/award of 9,250 derivative shares on June 10, 2026. The filing reports an acquisition at $0.00 per share (transaction code A), meaning this was a compensatory award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (appears timely under the 2-business-day rule).
• Amount: 9,250 derivative shares granted; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in this filing.
• Footnote (F1): The option shares vest on the earlier of (a) the next annual stockholders’ meeting following June 10, 2026 (or immediately prior if the director’s service ends due to non‑re election), or (b) the first anniversary of June 10, 2026—subject to continuous service through the vesting date.
• Transaction code: A (award/grant).

Context

• This is a typical director compensation grant (a derivative award) that vests over time; it does not represent an immediate market purchase or sale. Such awards are common for board service and do not by themselves indicate a buy or sell signal.